Choncept is a biotech company focused on development of new technology to produce chondroitin from fermentation of recombinant bacteria to replace the current chondroitin source of beef and other animal by-products. Chondroitin produced by the gene patented by Choncept is unsulfated which can be sulfated to produce chondroitin similar to that isolated from animal sources. The unsulfated chondroitin may also be of interest as a biomaterial. Chondroitin produced recombinantly may be significantly less expensive to produce than current methods that rely on animal by-products. Modified chondroitin, dermatan sulfate, has properties as an anti-coagulant, an important pharmaceutical market.

Choncept is working with our partner Biological E. Ltd. to develop:

• Scale-up of fermentation and sulfation technology to produce chondroitin in the $400 million nutraceutical joint market
• Produce chondroitin with different sulfation than natural chondroitin, including unsulfated, as a biomaterial in estimated $1 billion market

Choncept is seeking collaborative partners in several areas of development:

• Partners with existing market channels for the distribution of nutraceutical and medical grade chondroitin sulfate
• Partners for Dermatan sulfate development as an anti-coagulant for the $2 billion anti-coagulation market